OPA1 mitochondrial dynamin like GTPase
Ultimo aggiornamento 8 maggio 2023
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Versione audio
- Aggiungi alle fonti preferite su Google
L OPA1 gene provides instructions for making a protein that is found in cells and tissues throughout the body. The OPA1 protein is active in the inner membrane of cell structures called mitochondria, which are the energy-producing centers in cells. Mitochondria are dynamic structures that change shape through processes called fission (splitting into smaller pieces) and fusion (combining pieces). Changes in shape are necessary for mitochondrial function and the production of new mitochondria. The OPA1 protein helps to regulate the shape of mitochondria by playing a key role in the fusion process.
Normal function
L OPA1 gene provides instructions for making a protein that is found in cells and tissues throughout the body. The OPA1 protein is active in the inner membrane of cell structures called mitochondria, which are the energy-producing centers in cells. Mitochondria are dynamic structures that change shape through processes called fission (splitting into smaller pieces) and fusion (combining pieces). Changes in shape are necessary for mitochondrial function and the production of new mitochondria. The OPA1 protein helps to regulate the shape of mitochondria by playing a key role in the fusion process.
The OPA1 protein is also involved in a process that takes place in mitochondria called oxidative phosphorylation, from which cells derive much of their energy. Additionally, the OPA1 protein plays a role in the maintenance of the DNA within mitochondria, called mitochondrial DNA (mtDNA), and in controlled cell death (apoptosis).
Conditions referring to this gene or chromosome
Altri nomi
dynamin-like 120 kDa protein, mitochondrial
FLJ12460
KIAA0567
MGM1
mitochondrial dynamin-like GTPase
NPG
NTG
OPA1_HUMAN
Related patient information and medicines
Patient information leaflet
Debolezza muscolare
This leaflet looks at types of debolezza muscolare and discusses the wide range of problems which can cause them. Some of these causes are very common and others are very rare. Examples include: Glycogen storage diseases (in which glycogen, a carbohydrate, infiltrates muscles as well as other or... Even rarer, mitochondrial diseases which occur when.
Patient information leaflet
Sindrome da vomito ciclico
Cyclical vomiting syndrome is a condition which occurs mainly in children but can also affect adults. It is more common in people who have migraines. ... The relationship between cyclical vomiting syndrome and migraines is well recognised. Some studies have suggested a link between cyclical vomiting syndrome e autonomic disturbances or.
Patient information leaflet
Posso assumere Berberina e Nexplanon insieme?
Berberine potrebbe reduce the effectiveness of the Nexplanon implant, which could increase the risk of an unplanned pregnancy. Our Controllo Interazioni Farmaci helps you check whether your prescriptions, over-the-counter medicines, e supplements are safe to take together. Simply search for your medicines to see potential interactions and what to do.
Patient information leaflet
Posso prendere Apixaban e Levomepromazina insieme?
Taking apixaban and levomepromazine together may increase your risk of bleeding. Levomepromazine can sometimes cause a drop in the number ... Simply search for your medicines to see potential interactions and what to do about them. Disclaimer This information is for general educational purposes only and should not be relied upon as a substitute.
Patient information leaflet
Posso assumere Collagene e Tamoxifene insieme?
There is no known direct interaction between collagen supplements and tamoxifen. Collagen is a protein found naturally in the body, and taking it as a supplement is generally considered safe alongside this medication. Why this happens Collagen is broken down into amino acids in the digestive tract, similar to eating protein-rich food. It does not.
Patient information leaflet
Posso assumere Royal sun e Shiitake insieme?
Both Royal Sun (Agaricus blazei) and Shiitake (Lentinula edodes) mushrooms contain high levels of beta-glucans, which are substances that stimulate the immune system. Taking them together may cause your immune system to become overactive. Both mushrooms can lower blood sugar levels and thin the blood. Taking them together might increase the risk.
Ulteriori letture e riferimenti
- OPA1 mitochondrial dynamin like GTPase; MedlinePlus, National Library of Medicine.
- Amati-Bonneau P, Milea D, Bonneau D, Chevrollier A, Ferre M, Guillet V, Gueguen N, Loiseau D, de Crescenzo MA, Verny C, Procaccio V, Lenaers G, Reynier P. OPA1-associated disorders: phenotypes and pathophysiology. Int J Biochem Cell Biol. 2009 Oct;41(10):1855-65. doi: 10.1016/j.biocel.2009.04.012. Epub 2009 Apr 21.
- Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissiere A, Campos Y, Rivera H, de la Aleja JG, Carroccia R, Iommarini L, Labauge P, Figarella-Branger D, Marcorelles P, Furby A, Beauvais K, Letournel F, Liguori R, La Morgia C, Montagna P, Liguori M, Zanna C, Rugolo M, Cossarizza A, Wissinger B, Verny C, Schwarzenbacher R, Martin MA, Arenas J, Ayuso C, Garesse R, Lenaers G, Bonneau D, Carelli V. OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain. 2008 Feb;131(Pt 2):338-51. doi: 10.1093/brain/awm298. Epub 2007 Dec 24.
- Bonneau D, Colin E, Oca F, Ferre M, Chevrollier A, Gueguen N, Desquiret-Dumas V, N'Guyen S, Barth M, Zanlonghi X, Rio M, Desguerre I, Barnerias C, Momtchilova M, Rodriguez D, Slama A, Lenaers G, Procaccio V, Amati-Bonneau P, Reynier P. Early-onset Behr syndrome due to compound heterozygous mutations in OPA1. Brain. 2014 Oct;137(Pt 10):e301. doi: 10.1093/brain/awu184. Epub 2014 Jul 10. No abstract available.
- Chao de la Barca JM, Prunier-Mirebeau D, Amati-Bonneau P, Ferre M, Sarzi E, Bris C, Leruez S, Chevrollier A, Desquiret-Dumas V, Gueguen N, Verny C, Hamel C, Milea D, Procaccio V, Bonneau D, Lenaers G, Reynier P. OPA1-related disorders: Diversity of clinical expression, modes of inheritance and pathophysiology. Neurobiol Dis. 2016 Jun;90:20-6. doi: 10.1016/j.nbd.2015.08.015. Epub 2015 Aug 23.
- Delettre-Cribaillet C, Hamel CP, Lenaers G. Optic Atrophy Type 1 - RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY. 2007 Jul 13 [updated 2015 Nov 12]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1248/
- Ferre M, Bonneau D, Milea D, Chevrollier A, Verny C, Dollfus H, Ayuso C, Defoort S, Vignal C, Zanlonghi X, Charlin JF, Kaplan J, Odent S, Hamel CP, Procaccio V, Reynier P, Amati-Bonneau P. Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations. Hum Mutat. 2009 Jul;30(7):E692-705. doi: 10.1002/humu.21025.
- Ferre M, Caignard A, Milea D, Leruez S, Cassereau J, Chevrollier A, Amati-Bonneau P, Verny C, Bonneau D, Procaccio V, Reynier P. Improved locus-specific database for OPA1 mutations allows inclusion of advanced clinical data. Hum Mutat. 2015 Jan;36(1):20-5. doi: 10.1002/humu.22703. Epub 2014 Dec 1.
- Formichi P, Radi E, Giorgi E, Gallus GN, Brunetti J, Battisti C, Rufa A, Dotti MT, Franceschini R, Bracci L, Federico A. Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy (ADOA) patients with mutations in the opa1 gene. J Neurol Sci. 2015 Apr 15;351(1-2):99-108. doi: 10.1016/j.jns.2015.02.047. Epub 2015 Mar 6.
- Schimpf S, Fuhrmann N, Schaich S, Wissinger B. Comprehensive cDNA study and quantitative transcript analysis of mutant OPA1 transcripts containing premature termination codons. Hum Mutat. 2008 Jan;29(1):106-12. doi: 10.1002/humu.20607.
- Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, Toscano A, Musumeci O, Valentino ML, Caporali L, Lamperti C, Tallaksen CM, Duffey P, Miller J, Whittaker RG, Baker MR, Jackson MJ, Clarke MP, Dhillon B, Czermin B, Stewart JD, Hudson G, Reynier P, Bonneau D, Marques W Jr, Lenaers G, McFarland R, Taylor RW, Turnbull DM, Votruba M, Zeviani M, Carelli V, Bindoff LA, Horvath R, Amati-Bonneau P, Chinnery PF. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010 Mar;133(Pt 3):771-86. doi: 10.1093/brain/awq007. Epub 2010 Feb 15.
- Zanna C, Ghelli A, Porcelli AM, Karbowski M, Youle RJ, Schimpf S, Wissinger B, Pinti M, Cossarizza A, Vidoni S, Valentino ML, Rugolo M, Carelli V. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain. 2008 Feb;131(Pt 2):352-67. doi: 10.1093/brain/awm335.
Partecipa alla conversazione
Condividi i tuoi pensieri o esperienze con gli altri nel nostro comunità di pazienti.
Chiedi, condividi, connettiti.
Esplora le discussioni, fai domande e condividi esperienze su centinaia di argomenti di salute.
Iscriviti alla newsletter di Patient
La tua dose settimanale di consigli sulla salute chiari e affidabili - scritti per aiutarti a sentirti informato, sicuro e in controllo.
Abbonandoti accetti i nostri Informativa sulla Privacy. Puoi annullare l'iscrizione in qualsiasi momento. Non vendiamo mai i tuoi dati.